Nexalin Technology announces initiation of patient recruitment in UCSD study

Nexalin Technology (NXL) announced that following Institutional Review Board, IRB, approval, the University of California, San Diego, UCSD, has received the first shipment of HALO Clarity devices to commence its clinical trial evaluating the treatment of mild traumatic brain injury and post-traumatic stress disorder in military personnel and the civilian population. Patient recruitment for the study is now set to begin immediately. This milestone follows the successful IRB approval, pilot testing and evaluation of Nexalin’s Halo technology at UCSD. The study will evaluate Nexalin’s proprietary Deep Intracranial Frequency Stimulation technology, which delivers non-invasive deep-brain stimulation without the use of drugs or invasive procedures.